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Abstract
Many effects of nitric oxide (NO) are mediated by the activation of guanylyl cyclases and subsequent production of the
second messenger cyclic guanosine-39,59-monophosphate (cGMP). cGMP activates cGMP-dependent protein kinases
(PRKGs), which can therefore be considered downstream effectors of NO signaling. Since NO is thought to be involved in
the regulation of both sleep and circadian rhythms, we analyzed these two processes in mice deficient for cGMP-dependent
protein kinase type I (PRKG1) in the brain. Prkg1 mutant mice showed a strikingly altered distribution of sleep and
wakefulness over the 24 hours of a day as well as reductions in rapid-eye-movement sleep (REMS) duration and in non-REM
sleep (NREMS) consolidation, and their ability to sustain waking episodes was compromised. Furthermore, they displayed a
drastic decrease in electroencephalogram (EEG) power in the delta frequency range (1–4 Hz) under baseline conditions,
which could be normalized after sleep deprivation. In line with the re-distribution of sleep and wakefulness, the analysis of
wheel-running and drinking activity revealed more rest bouts during the activity phase and a higher percentage of daytime
activity in mutant animals. No changes were observed in internal period length and phase-shifting properties of the
circadian clock while chi-squared periodogram amplitude was significantly reduced, hinting at a less robust oscillator. These
results indicate that PRKG1 might be involved in the stabilization and output strength of the circadian oscillator in mice.
Moreover, PRKG1 deficiency results in an aberrant pattern, and consequently a reduced quality, of sleep and wakefulness,
possibly due to a decreased wake-promoting output of the circadian system impinging upon sleep.
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Introduction
Life evolved in an environment of periodic recurrence of light
and darkness. These steady changes have led to the incorporation
of daily biological rhythms in order to schedule biochemical
processes to their optimal phase during the 24 hours of a day. In
mammals, the day can roughly be divided into an activity phase,
during which physical activity is predominant, and a rest phase,
during which repair mechanisms are activated and brain function
alters into a state of sleep. Sleep is mainly controlled by two
mechanisms: A homeostatic component regulates need and
intensity of sleep according to the time spent awake or asleep,
whereas a circadian component schedules sleep and wakefulness to
the appropriate times within one day [1]. For the homeostatic
process, a reliable index is provided by the amplitude and
prevalence of delta (1 to 4 Hz) oscillations in the EEG of NREMS,
also termed delta power. Delta power is high at the onset of sleep
and consecutively decreases as animals rest. Sleep deprivation
induces a predictable increase in delta power during subsequent
sleep. For the circadian process in rodents, reliable information on
the internal period length of the autonomous clock mechanism
and the ability of the clock to adapt to changes in lighting
schedules can be obtained by recording wheel-running activity.
However, deciphering the molecular base of sleep is difficult
because the contributions of the homeostatic and circadian
processes are not easy to separate.
Increasing evidence hints at an involvement of NO signaling in
the regulation of sleep, especially in that of NREMS [2–4] and
sleep homeostasis [5,6]. Variations of brain NO levels during the
sleep-wake cycle were observed in rats [7,8], and plasma levels of
cGMP, a second messenger downstream of NO (reviewed in [9]),
were found to be elevated at night in humans [10]. Moreover, NO
and cGMP have been suggested to be involved in the modulation
of circadian rhythmicity [11]. We therefore decided to investigate
whether the NO-cGMP signaling pathway is involved in sleep
regulation.
Many effects of NO in the nervous system are mediated via
cGMP, which may act through various intracellular receptors,
among them a family of serine/threonine kinases, the cGMP-
dependent protein kinases (PRKG, also abbreviated cGK or PKG;
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Prkg1 and Prkg2. Whereas PRKG2 has been reported to play a role
in night-to-day progression and phase shifting of the circadian
clock [13,14], PRKG1 has been implicated in synaptic plasticity
and learning (reviewed in [15]). Interestingly, PRKG1 is also
expressed in brain regions that are involved in the regulation of
sleep and circadian rhythms, such as the suprachiasmatic and
other hypothalamic nuclei [16–18]. Furthermore, in C. elegans,
overexpression of egl-4, a gene encoding for a cGMP-dependent
protein kinase, caused adult animals to stop moving and feeding,
whereas a lack of egl-4 reduced behavioral quiescence in these
animals [19]. These results suggest that cGMP-PRKG signaling
promotes lethargus, a sleep-like state, in C. elegans.
To characterize the influence of PRKG1 on sleep and circadian
rhythmicity in mammals, we analyzed two different mouse models
lacking functional PRKG1 in the brain. We observed an altered
pattern of sleep and reduced delta power under baseline
conditions, indicating decreased sleep need in Prkg1 mutants.
After sleep deprivation, the difference in delta power disappeared,
while the rebound in sleep time was increased in mutant mice.
Furthermore, they displayed increased daytime activity and slower
adaptation to alterations of the light-dark cycle pointing at a weak
circadian oscillator. Taken together, our findings indicate that
cGMP signaling via PRKG1 plays an important role in
mammalian sleep regulation and timing of physical activity over
the 24 hours of a day.
Results
A complete Prkg1 knock-out leads to premature death at
approximately 6 weeks of age, presumably due to smooth muscle
dysfunction [20]. We therefore used two different conditional
mouse models lacking Prkg1 in the nervous system. In one model,
Prkg1 expression was rescued only in smooth muscle (SM) cells of
Prkg1 null mutants (Prkg1
SMr mice) [21]. The other model was
generated by Cre/lox-mediated neuron-specific inactivation of the
Prkg1 gene using the Nes-Cre line [22]; these mouse mutants were
termed Prkg1 brain knock-out mice (Prkg1
BKO mice; see Fig. 1A and
methods section). The recombination properties of Nes-Cre mice
were confirmed by crossing them to R26R Cre reporter mice [23]
and subsequent X-Gal staining of the brain for Cre activity
(Fig. 1B). Western blot analysis (Fig. 1C) and immunohistochem-
istry (Fig. 1D) demonstrated an absence, or drastic reduction, of
PRKG1 expression in various brain regions of Prkg1
BKO mice.
Since there are many brain regions involved in sleep regulation
and the response to sleep deprivation (reviewed in [4]), Prkg1
SMr
mice, in which there is no risk of residual PRKG1 expression in
any part of the nervous system, were chosen for sleep analysis.
Circadian behavior, however, was studied in both lines. Circadian
rhythms in overt behaviors are almost exclusively controlled by the
suprachiasmatic nuclei (SCN). Therefore, we confirmed Cre
activity in the SCN by X-Gal staining of R26R reporter mice
and abolition of PRKG1 expression in the SCN of Prkg1
BKO mice
by immunohistochemistry (Fig. 1D) and consequently used also
these mutants to assess the influence of PRKG1 on circadian
rhythmicity.
Prkg1
SMr mice show a re-distribution of sleep and
wakefulness
Although Prkg1
SMr mice did not differ in total time spent awake
or asleep, the distribution of sleep and waking over the baseline
day was markedly altered compared to control mice (Table 1,
Figs. 2A, B). Mice are usually more active and awake during the
dark as compared to the light period. The amplitude of this light-
dark difference in sleep amount was significantly reduced in
Prkg1
SMr mice (Table 1). In comparison to control animals,
Prkg1
SMr mice were awake more in the first 7 h of the baseline light
period and slept more during the hour preceding dark onset and
the three subsequent hours (Figs. 2A, B). This pattern resulted in a
sinusoidal time course of differences in accumulated time spent
awake (Fig. 2B).
Lack of Prkg1 did not equally affect NREMS and REMS.
Although NREMS time did not differ between genotypes, Prkg1
SMr
mice spent less time in REMS than controls (Table 1, Fig. 2A).
This reduction was present in both lighting conditions and the
light-dark difference was not affected by genotype (Table 1). An
analysis of the relative distribution of REMS over the 24 h
baseline day (i.e., the percentage of each animal’s total REMS
during baseline) revealed, however, a redistribution also for this
state (Fig. 2B). Prkg1
SMr mice displayed less REMS in the first half
of the light period, a deficit that was entirely compensated in the
second half and, conversely, showed more REMS in the first half
of the dark period, a surplus that was again lost in the second half.
In contrast the effects on NREMS were the mirror image of those
described above for wakefulness to a large extent (Table 1,
Figs. 2A, B).
Rebound sleep is increased in Prkg1
SMr mutants
We next wanted to determine whether homeostatic regulation
of sleep was altered in Prkg1
SMr mice. Lack of Prkg1 was found to
affect the sleep recovery pattern after sleep deprivation, especially
within the first 5 h (Fig. 2C; compare 30–35 h of recovery to 6–
11 h of baseline). Over this period, Prkg1
SMr mice accrued a 2.9-
fold increase in extra NREMS time and a 3.7-fold increase in
extra REMS time compared to control mice. Moreover, in
Prkg1
SMr mice rebound sleep was apparent already after 2 h
whereas in control mice, sleep time was initially reduced and only
after 6 h did accumulated values exceed baseline (Fig. 2C). In the
dark period, these differences between genotypes persisted
although significance levels were no longer reached.
Prkg1
SMr mice display a marked decrease in EEG delta
power
The EEG power in the delta frequency range (1–4 Hz; i.e.,
EEG delta power) during NREMS is widely used to index sleep
need and we therefore followed the dynamics of this variable
throughout the 2-day experiment. Striking differences between
genotypes were observed during baseline (Fig. 3A). Prkg1
SMr mice
showed unusually low levels of EEG delta power at sleep onset
(i.e., light onset) when sleep need and EEG delta power in mice
tend to be highest (see control mice in Fig. 3A). Values remained
lower for most of the initial 6 h of the light period. During the dark
(active) period, EEG delta power increased in control mice,
consistent with sleep need building up when waking prevails, and
again was importantly reduced in Prkg1
SMr mice. While no overall
differences in time spent awake were found (Table 1), Prkg1
SMr
mice were awake more in the 6 h preceding light onset (Prkg1
SMr
vs. control mice: 3.360.2 h vs. 2.860.1 h; P=0.028; 2-sided t-
tests; data not included in Fig. 2 but consistent with observations in
18–24 h). Together, these observations strongly suggest that Prkg1
deficiency alters the relationship between time spent awake and
subsequent EEG delta power. However, under conditions of
enforced wakefulness this relationship seemed normalized: delta
power levels reached after 6 h of sleep deprivation and their
subsequent time course during recovery did not differ between
genotypes (Fig. 3A). Relative delta power after sleep deprivation,
expressed as percent of baseline values, was elevated in Prkg1
SMr
during the first recovery interval only (Fig. 3B).
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Prkg1
SMr mice
The pronounced baseline differences in EEG delta power might
be due to differences in the quality of waking impeding a build-up
of sleep need. The spectral composition of the waking EEG did not
greatly differ between the two genotypes. This was true for the
entire 24 h baseline recordings (Fig. S1) as well as during the last
6 h of the dark period; i.e., the period preceding the time when
genotype differences in EEG delta power were maximal (data not
shown). When rats spent more of their waking time exploring,
EEG delta power in subsequent NREMS was reported to be
higher [24]. We therefore analyzed theta activity (4–8 Hz) in the
Figure 1. Generation of Prkg1
BKO mice. (A) Strategy for conditional disruption of the murine Prkg1 gene. Depicted are the Prkg1 wild-type locus
(+), the loxP-flanked conditional Prkg1 allele (L2), and the excised Prkg1 null allele (L2) obtained after Cre-mediated recombination of the L2 allele.
The filled box denotes exon 10 of the murine Prkg1 gene that encodes part of the ATP-binding site. Filled triangles indicate loxP sequences. The open
box represents a thymidine kinase (tk)-neomycin resistance (neo) fusion gene. Restriction sites for BamHI, EcoRI, HindIII, NcoI, and NheI are indicated
by B, E, H, Nc, and Nh, respectively. (B) X-Gal staining of a brain (sagittal view) of Nes-Cre;R26R reporter mice for Cre activity. (C) Western blot analysis
of PRKG1 expression in various brain regions of control and Prkg1
BKO mutant mice. The p42/44 mitogen-activated protein kinase (MAPK) was used as
loading control. (D) Cre activity (left panels) and PRKG1 expression (middle and right panels) in the dorsomedial hypothalamus (DMH; upper panels)
and suprachiasmatic nucleus (SCN, lower panels). Cre activity was monitored by X-Gal staining of cryosections of brains from Nes-Cre;R26R reporter
mice. PRKG1 was detected by immunohistochemistry on paraffin sections of brains from control mice (middle panels) and Prkg1
BKO mice (right
panels).
doi:10.1371/journal.pone.0004238.g001
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differences between genotypes were observed in the frequency or
peak amplitude of EEG theta activity during the last 6 h of the
baseline dark period or in the duration and distribution of
wakefulness with distinct theta activity (i.e., theta-dominated
wakefulness; data not shown). One parameter that greatly differed
between the two genotypes was, however, waking episode duration
(Fig. S2). Prkg1
SMr mice spent more of their waking time in shorter
waking episodes (with durations between 16 s and 2 min) and
substantially less time in long waking episodes. Whereas in control
mice, episodes longer than 17 min contributed to 35% of the total
time spent awake, in Prkg1
SMr mice only 11% was spent in these
longer waking bouts. Thus, the inability to sustain longer periods
of waking might have contributed to a reduced build-up of sleep
need in Prkg1
SMr mice.
It also appears that Prkg1 affects sleep quality. Fragmentation of
NREMS can be quantified by counting the number of short (,60 s)
NREMS episodes [25]. NREMS was severely fragmented in
Prkg1
SMr mice since they showed more short and less long episodes
(short: 68.668.4 vs. 43.363.6; P=0.016; long NREMS episodes:
17.760.8 vs. 19.860.3 P=0.030; post-hoc 2-sided t-tests; all values
expressed per hour of NREMS). Accordingly, the frequency
distribution of NREMS episode duration was shifted towards
shorter episodes in Prkg1
SMr mice(Fig. S2). NREMS quality was also
assessed by inspection of the spectral composition of the EEG
during this state. EEG power density was markedly lower in
Prkg1
SMr than in control mice in the low delta (0.75–2.25 Hz)
frequency range and to a lesser extent also in the high delta (3.25–
4.75 Hz) and beta (16–21 Hz) ranges (Fig. 3C). The reduction in
EEG power in the low delta frequency band persisted even after
taking genotype differences in the overall EEG amplitude into
account. No significant changes between genotypes were observed
in the EEG spectra in REMS and wakefulness (Fig. S1).
Slow and fast delta frequencies are not equally affected
An additional factor that might play a role in the baseline
differences in EEG delta power is the 2-fold decrease in the EEG
activity in the low delta frequencies (1.0–2.25 Hz) during NREMS
observed in Prkg1
SMr mice (see above). As a consequence of this,
EEG delta power, calculated over the entire delta frequency range
(1–4 Hz), might reflect sleep need less accurately. We therefore
analyzed the sleep-wake dependent dynamics of EEG delta power
for slow and fast delta frequencies separately (Fig. S3). For both
genotypes the changes in the faster delta frequencies clearly
respond more precisely to the changes in sleep and waking. This is
especially obvious in the dark periods, when relative power in the
slow delta frequencies was importantly lower than in the faster
delta frequencies. Also during recovery from sleep deprivation,
both the positive and subsequent negative rebound in EEG activity
in the fast delta frequencies were lacking in the slow frequencies in
control mice. Despite these changes, sleep deprivation affected
EEG activity in the two delta bands similarly in the two genotypes,
and the altered NREMS EEG spectra observed for Prkg1
SMr mice
during baseline were present also after sleep deprivation (Fig. 3D,
see also the fast-to-slow delta power ratio in Fig. S3B).
The amplitude of circadian rhythmicity is decreased in
Prkg1 mutant mice
Since re-distribution of sleep might be influenced by the
circadian clock, we monitored wheel-running activity of Prkg1
SMr
and Prkg1
BKO mutants as well as their respective controls under
different lighting conditions. Animals were entrained to a 12 hours
light/12 hours dark cycle (LD 12:12) and subsequently released
into constant darkness (DD) or constant light (LL). We observed
that animals, as expected, were mostly active during the dark
period in LD and that all genotypes were able to maintain
circadian, i.e., rhythmic, wheel running activity in DD (Fig. 4A–
D). Total activity under all lighting conditions tested was not
different for Prkg1
BKO mutants as compared to control animals
whereas Prkg1
SMr mutant mice showed drastically reduced activity
both in LD and DD (Fig. 4E). Prkg1
SMr mutants were therefore not
subjected to LL since in LL, activity can be expected to be even
lower. The reduced wheel running activity of Prkg1
SMr mice was
not due to a decreased general locomotor activity, since an open
field test in Prkg1
SMr mice revealed no differences in total distance,
mean speed and percentage of time spent active between Prkg1
SMr
mice and controls (Fig. S4). This is in line with the observation that
there is no difference in theta power and theta-dominated
wakefulness between these two genotypes (see above).
Internal period length; i.e., tau, in DD did not differ between
either mutant and its respective control, whereas a slight difference
in the period lengths determined under LL conditions was
observed for Prkg1
BKO mutant and control mice (Fig. 4F). Chi
square periodogram amplitude, which has been used as a measure
of the robustness of circadian rhythms [26,27], was found to be
significantly lower in both mutant strains in DD, but not in LL in
Prkg1
BKO mutant mice (Fig. 4G). This hints at a possible role of
PRKG1 in the stabilization of the circadian oscillator. In order to
investigate this phenomenon in more detail, additional wheel-
running experiments were performed. This time, we used
exclusively Prkg1
BKO mutant and control animals since they
displayed overall higher chi square periodogram amplitudes than
Prkg1
SMr mutants and controls, indicating a more stable oscillator.
Prkg1
BKO mice show higher onset errors and reduced
activity after chronic jet-lag
Since PRKG2 has been implicated in clock resetting [13], we
tested whether Prkg1
BKO animals, as compared to control mice,
reacted differently to a nocturnal light pulse (Fig. S5). We observed
no differences for light pulses applied at ZT14 or ZT22 (beginning
and end of the subjective night, respectively), however. From this
we conclude that PRKG1 probably does not play an important
role in the acute light-signaling pathway that influences phase
Table 1. Time-spent awake and asleep in baseline.
Genotype W NREMS REMS
24 h control 12.17 (0.57) 9.78 (0.51) 2.05 (0.08)
Prkg1
SMr 12.72 (0.29) 9.70 (0.25) 1.58 (0.13)*
12 h light control 4.60 (0.17) 6.05 (0.15) 1.35 (0.04)
Prkg1
SMr 5.26 (0.23)* 5.64 (0.20) 1.10 (0.09)*
12 h dark control 7.57 (0.40) 3.73 (0.36) 0.69 (0.05)
Prkg1
SMr 7.46 (0.11) 4.06 (0.12) 0.48 (0.05)*
L-D difference control 22.98 (0.24) 2.31 (0.22) 0.66 (0.04)
Prkg1
SMr 22.19 (0.22)* 1.57 (0.22)* 0.62 (0.06)
Mean (SEM; n=7) time in hours spent awake (W), in NREMS, and REMS during
baseline. Values were averaged over the entire day (24 h) and for the two
lighting conditions separately (12 h light and 12 h dark). The light-dark (L-D)
differences were calculated as well. Genotype affected the 24 h values of REMS
and the LD distribution of W and NREMS [2-way ANOVA with factors ‘genotype’
(P=0.41, 0.89, and 0.010) and ‘LD-condition’ (repeated measures: P,0.0001)
and their interaction (P=0.034, 0.033, and 0.58, for W, NREMS, and REMS,
respectively)]. Asterisks indicate significant differences between genotypes
(P,0.05; post-hoc 2-sided t-tests).
doi:10.1371/journal.pone.0004238.t001
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(see above) indicate, though, that PRKG1 might be implied in the
integration of external light cues, and possibly in the determination
of daylength since Prkg1
BKO mice appear to have a longer circadian
day under LL conditions (Fig. 4F).
An important cue to determine the length of a day is the lights
off-signal, which, in nocturnal animals, usually coincides with the
onset of activity. Therefore we tested how well Prkg1
BKO mice
entrained to this cue. We found that these mutants had a less
precise onset of wheel-running activity (Fig. 5A) as compared to
control mice, which is in accordance with the observed reduction
in chi-square periodogram amplitude and a weaker oscillator. This
phenomenon was observed for light intensities of 400 and 50 lux
but disappeared when only 10 lux were employed, probably due to
difficulties in distinguishing between light and dark phase already
in control animals (Fig. 5A). Under constant conditions (DD and
LL), the two strains also showed comparable onset errors (Fig. 5A).
Because of the differences in onset errors in LD, we tested how
Prkg1
BKO mutant and control mice reacted to chronic jet lag
(4 hour advance every 2 days). Under these conditions, a constant
re-adaptation to the changes in lighting schedule is required,
which is very stressful for animals with a weak oscillator.
Interestingly, total activity of mutants was reduced directly after
chronic jet lag, which might be a sign of a higher stress level
caused by the irregular lighting schedule, but went back up to
control levels when the mice were kept again in a regular LD cycle
(Fig. 5B), consistent with a recovery under steady conditions.
These observations suggest that Prkg1
BKO mutant mice are not able
to determine light-dark transitions as precisely as control animals,
and that this has behavioral consequences in a jet lag protocol.
Figure 2. Amount and distribution of wakefulness, NREMS, and REMS during baseline and recovery from sleep deprivation. (A) Time
course of mean (61 SEM) number of minutes spent in each state for consecutive 1 h intervals (Prkg1
SMr: filled symbols; control: open symbols) for the
48 h of the experiment. 0–24 h, baseline; 24–30 h, sleep deprivation; 30–48 h, recovery; W, wakefulness; N, NREMS; R, REMS; SD, sleep deprivation. (B)
Summary of genotype differences in the relative distribution of the three behavioral states during baseline. Hourly, integrated values are first
expressed as % of the total 24 h amount of each state within individuals (see Methods). Mean (61 SE of the difference) Prkg1
SMr – control differences
in % accumulated are depicted. Gray lines represent fitted sine functions. Genotype affected the baseline time course of W and N but not of R [2-way
ANOVA with factors ‘genotype’ (P=0.41, 0.89, and 0.010) and ‘time’ (0–24; repeated measures: P,0.0001) and their interaction (P=0.0012, 0.0007,
and 0.064); P-values for W, N, and R, respectively]. (C) Recovery time course of time spent asleep lost during the 6 h SD. Hourly values were first
expressed as differences (in min) between corresponding intervals during baseline (30–48 h vs. 6–24 h) within individuals, and then accumulated (see
Methods). Values represent mean (61SEM) accumulation curves for each genotype for N (top) and R (bottom panel). SD affected the amount and
time course of time spent asleep [3-way ANOVA with factors ‘genotype’ (P=0.24 and 0.25), ‘SD’ (recovery vs. baseline; repeated measures; P=0.0054
and ,0.0001) and ‘time’ (6–24 vs. 30–48; repeated measures: P,0.0001); interactions ‘genotype’6‘SD’ (P=0.56 and 0.24), ‘genotype’6‘time’
(P=0.0009 and 0.0001), ‘SD’6‘time’ (P=0.042 and ,0.0001); P-values for N and R, respectively]. Filled and open bars at the bottom of each panel
connect intervals for which accumulated sleep time differed from baseline for Prkg1
SMr and control mice, respectively (P,0.05; post-hoc 2-sided
paired t-tests). In all panels, gray areas denote the dark periods and gray diamonds indicate 1 h intervals in which values significant differed between
genotypes (P,0.05; post-hoc 2-sided t-tests).
doi:10.1371/journal.pone.0004238.g002
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mutant mice
The imprecision of determination of light offset in Prkg1
BKO
mice caused a higher extent of wheel-running activity during the
light phase and thus was reflected in an increase of daytime activity
at 400 lux and 50 lux (Fig. 5C), which suggests less sleep in the rest
(light) phase. In accordance with this, in the activity period (dark
phase), the number of longer rest bouts of 30 minutes to two hours
was higher (Fig. 5D), supporting the notion that Prkg1
BKO mice
show an altered sleep distribution (Fig. 2). Wheel-running activity
was increased during the light phase and decreased during the
dark phase in the mutants (Fig. 5E). These findings parallel our
observation that Prkg1
SMr mice display more wakefulness in the
light period (Fig. 2A, baseline).
We finally chose a complementary approach that allowed us to
analyze circadian rhythmicity and basal entrainment to light-dark
cycles without the problems associated with the reduced wheel
running activity of Prkg1
SMr mice. To this end, we monitored
drinking activity of both Prkg1
BKO and Prkg1
SMr mice and their
respective controls in LD 14:10. Both mutants were found to
consume a significantly higher percentage of their total water
intake during the light phase, while total drinking volume was not
different between genotypes (Fig. 5F, G). These observations
clearly confirm the findings of sleep and wheel running analysis,
Figure 3. Time course of EEG delta power and EEG spectra during NREMS. (A) Time course of mean (61SEM) relative levels of EEG delta
(1.0–4.0 Hz) power for the 48 h of the experiment (Prkg1
SMr: filled symbols; control: open symbols). Values were expressed as % of the lowest levels
reached in baseline (8–12 h; see Methods for details). The dynamic range of baseline changes in delta power was greatly reduced in Prkg1
SMr mice
compared to controls while during recovery from sleep deprivation (SD) this genotype difference disappeared [2-way ANOVA with factors ‘genotype’
(P=0.0063 and 0.53) and ‘time’ (repeated measures: P,0.0001) and their interaction (P=0.017 and 0.15); P-values for baseline and recovery,
respectively]. Gray areas denote the dark periods. (B) Effect of SD on EEG delta power during the light period. The first 8 values after recovery sleep
onset were expressed as % of the first 8 values after sleep (or light) onset in baseline within individual mice. Values represent means61SEM. (C)
Spectral composition of the NREMS EEG during baseline (upper panel; absolute values 0.75–45 Hz at 0.25 Hz resolution, lower panel: % difference
between genotypes). EEG power density was markedly lower in Prkg1
SMr than control mice in the low delta (0.75–2.25 Hz) frequency range and to
smaller extend also in the high delta (3.25–4.75 Hz) and beta (16–21 Hz) ranges. [2-way ANOVA with factors ‘genotype’ (P=0.0072) and ‘EEG
frequency’ (repeated measures, 0.75–45 Hz: P,0.0001) and their interaction (P=0.0009)]. EEG frequency was plotted on a logarithmic scale to better
illustrate differences in the lower frequencies. (D) Upper panel: NREMS EEG spectra during the first interval after sleep onset after SD (solid lines; see
A) and the corresponding time-of-day during baseline (dashed lines; see A interval 7). Lower panel: % recovery/baseline change (Black lines: Prkg1
SMr,
gray lines: control). In all panels, gray diamonds at the bottom indicate times at or frequency bins in which values significant differed between
genotypes (P,0.05; post-hoc 2-sided t-tests). In Panels A and D filled and open bars connect intervals for which values differed from baseline for
Prkg1
SMr and control mice, respectively (P,0.05; post-hoc 2-sided paired t-tests).
doi:10.1371/journal.pone.0004238.g003
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alters the activity pattern in favor of more daytime activity.
Discussion
In this study we report an altered distribution of sleep and
wakefulness as well as of wheel-running and drinking activity in
mice lacking functional PRKG1 in the brain. These results could
be confirmed independently using two different mouse models,
one in which Prkg1 expression was abolished selectively in the
nervous system and one in which it was restricted to smooth
muscle cells. Moreover, mutants displayed less REM sleep and a
more fragmented NREMS, a phenotype that has also been
observed in a rat model of sleep fragmentation [28], as well as a
drastic decrease in delta power under baseline conditions.
Although not all parameters were determined in both strains,
those analyses performed in parallel indicate that their phenotype
is largely identical: Neither of the mutants showed an altered
internal period length in DD, and the differences observed in chi
square periodogram amplitude as well as in drinking behavior
were the same for both mutant strains compared to their
respective controls. Furthermore, results for sleep and circadian
Figure 4. Circadian phenotype of Prkg1
BKO and Prkg1
SMr mutants. (A) and (C) Representative activity recordings (actograms) of Prkg1
BKO (A)
and Prkg1
SMr (C) mutant mice and their respective controls whose wheel-running activity is plotted as vertical bars in a double-plot format. Each
horizontal line represents two 24 h periods; the second (right) half of each line is repeated on the first (left) half of the following line. Mice were
entrained to LD 12:12 and subsequently released into DD (A, upper panels, and C) or LL (A, lower panels). Black and white bars on top depict the
distribution of dark and light periods during initial LD, shaded areas in the actograms indicate actual dark periods during the experiment. LD, light-
dark cycle; DD, constant darkness; LL, constant light. (B) and (D) Theoretical probability distributions for period lengths between 10 and 35 hours (chi
square periodograms) of the activity data obtained under DD (B, upper panels, and D) or LL (B, lower panels) for the same animals whose actograms
are shown in (A) and (C). The X coordinate of the peak indicates the internal period length of the free-running rhythm, the Y coordinate is a measure
of the robustness of the rhythm. Note that Y axis scales are the same for adjoining periodograms to make differences more readily visible. (E)–(G)
Total activity values (E), internal period length tau (F) and amplitude of chi square periodograms (G) for Prkg1
BKO and Prkg1
SMr mutants and their
respective controls in LD (only for activity), DD and LL (only for Prkg1
BKO mutants and controls). n=18 for Prkg1
BKO mutants, n=20 for the respective
controls for LD and DD; n=9 for Prkg1
BKO mutants, n=11 for controls for LL; n=6 for Prkg1
SMr mutants and the respective controls. ** p,0.01, *
p,0.05 as determined by unpaired t-test. LD, light-dark cycle; DD, constant darkness; LL, constant light.
doi:10.1371/journal.pone.0004238.g004
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BKO have a weakened circadian oscillator. (A) Onset errors of control and Prkg1
BKO mutant mice kept in LD 12:12 of the
indicated intensities, DD and LL were determined from the actograms. They are expressed as the average deviation of the actual onset from lights off
for LD and from a regression line drawn through all onsets for DD and LL. n=5 for both genotypes for LD 50 and 10 lx, n=11 for controls, n=9 for
Prkg1
BKO mutants for all other conditions. ** p,0.01, * p,0.05 as determined by unpaired t-test. LD, light-dark cycle; DD, constant darkness; LL,
constant light. (B) Control and Prkg1
BKO mutant mice were subjected to a lighting schedule mimicking chronic jet lag for 18 days (4 h forward phase
shift every two days, see diagram on top: black and white bars indicate distribution of dark and light phases). Total wheel-running activity was
quantified before the jet lag, directly after and two months after the treatment. n=11 for controls, n=9 for Prkg1
BKO mutants. * p,0.05 as
determined by unpaired t-test. (C) Daytime activity was determined for control and Prkg1
BKO mutant mice kept in LD 12:12 of the indicated
intensities. Activity recorded during the light phase is plotted as percentage of total activity. n=5 for both genotypes for 50 and 10 lx, n=20 for
controls and n=18 for Prkg1
BKO mutants for 400 lx. *** p,0.001, * p,0.05 as determined by unpaired t-test. (D) Control and Prkg1
BKO mutant mice
were kept in LD 12:12. Bouts of inactivity during the activity phase, e.g. the period of more or less continuous activity, were quantified from the
actograms. n=19 for controls, n=18 for Prkg1
BKO mutants. ** p,0.01, * p,0.05 as determined by unpaired t-test. (E) The average distribution of
activity over one day was analyzed for control and Prkg1
BKO mutant mice kept in LD 12:12. Black and white bars on top depict the distribution of dark
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total amount of sleep, wakefulness, drinking or wheel-running
activity, only their distribution over the 24 hours of a day was
changed in a way that indicates more activity, or wakefulness,
during the day and more sleep, or rest, during the night.
Previous findings about the involvement of NO and cGMP in
the regulation of sleep and wakefulness and sleep homeostasis are
not fully conclusive and partly contradictory. NO has been
reported to promote sleep in rats [29], and injection of an NO
donor caused an increase in NREMS [30]; in cats, however, it also
appears to be required for arousal [31]. Inhibition of NO synthase
(NOS) by L-NAME has been described to reduce both NREMS
and REMS in rats [32]; however, also the exact opposite effect has
been reported [33]. The specific neuronal NOS (nNOS) inhibitor,
7-nitro-indazole, has been demonstrated to decrease REMS
exclusively [33], to reduce both REMS and NREMS as well as
EEG amplitude [34], or to have most of all an effect on NREMS
[35], respectively. Inhibition of soluble guanylyl cyclase, which
generates cGMP upon activation by NO, promoted NREMS and
suppressed REMS [36].
Divergent findings might be due to variances in times of
treatment [37] and/or drug dose [30,35]. In addition, it is
important to note that not all effects of NO must be mediated via
cGMP and PRKGs. For instance, NO can signal in a cGMP-
independent manner via S-nitrosylation of target proteins [38]. In
any case, two of our main observations in mice deficient in
PRKG1 in the brain, namely reduced REM sleep and EEG
amplitude, have been made before in animals with impaired NO
signaling [32–34], implicating that the NO-cGMP-PRKG1
pathway might indeed be involved in sleep regulation. Further
support for this hypothesis comes from a study in mutant mice,
which revealed that abolition of nNOS, but not inducible NOS
(iNOS), reduced REMS in mice [39]. Given that under normal
conditions, iNOS is not expressed in the brain (reviewed in [40]), a
sleep-regulating pathway involving both nNOS and PRKG1
might be envisaged.
Delta power under baseline conditions was reduced in Prkg1
SMr
mice, which also has been described previously after L-NAME
treatment [37]. At the same time, more short NREMS episodes
were observed in the mutants. The prevalence of EEG delta
oscillation is thought to reflect the depth of NREMS and therefore
to correlate negatively with sleep fragmentation [41]. Marked
increases in the relative contribution of fast oscillations (39.0–
60.25 Hz) to the NREMS EEG, as those observed in Prkg1
SMr
mice (Fig. S1), have also been associated with a more disturbed
sleep and higher levels of cortical arousal during sleep [42].
Based on delta power, sleep homeostasis does not appear to be
altered in Prkg1
SMr mice because the drastic reduction in delta
power present under baseline conditions was no longer seen after
sleep deprivation. However, the marked increase in rebound sleep
(both REMS and NREMS), which was especially pronounced
immediately after sleep deprivation, suggests a role for PRKG1 in
these aspects of homeostatic sleep regulation.
Inhibition of NO signaling in the brain has been reported to
have the opposite effect, namely a decrease in sleep rebound, in
rats [5,6]; for mice, however, no data is available. It is conceivable
that the contrasting observations in mice and rats reflect species-
specific differences. Alternatively, the reduced capacity of Prkg1
SMr
mice to sustain long bouts of wakefulness might contribute to the
lower levels of EEG delta power reached in these mice because
sleep need does not substantially accumulate when sleep is
initiated after only a few minutes of wakefulness. Thus, the
considerable differences in delta power under baseline conditions
might be caused not by changes in the sleep homeostat, but by
changes in wake consolidation, which are also confirmed by the
circadian data, namely the observation that there are more long
rest bouts during the activity phase.
Inhibition of PRKGs has been shown to abolish phase advances
or to cause spontaneous phase delays in hamster and rat [43,44].
However, these effects appeared to be mediated by PRKG2 rather
than PRKG1 [14]. The absence of a resetting phenotype in Prkg1
mutant mice might also be explained by species-specific differenc-
es. Mice deficient for nNOS or endothelial NOS (eNOS), e.g., the
two NOS species expressed in the brain under non-pathological
conditions, were found to display normal phase shifts and an
internal period length comparable to their respective controls
[45,46]. NO signaling appears to have a stabilizing effect on the
oscillator, though, because treatment with NO donors has been
shown to revert the aging-induced decline of circadian rhythms
[47]. In agreement with this, treatment of mice with sildenafil, a
phosphodiesterase inhibitor which causes sustained cGMP-medi-
ated signaling, improves adaptation after jet lag [48]. These results
parallel our observations that, in the absence of PRKG1, mice do
not tolerate chronic jet lag as well as control animals.
The sleep data indicates that, in the absence of PRKG1, both
sleep and wakefulness are more fragmented and that their
distribution over the 24 hours of a day is altered. In accordance
with the sleep phenotype, wheel-running and drinking analysis
revealed increased activity of Prkg1 mutants during the day, when
rodents are usually not active. A higher fragmentation could also
be observed for the activity distribution during the active phase in
that Prkg1
BKO animals showed more long rest bouts (Fig. 5D). This
is in agreement with the accumulation of more REM sleep in
mutant mice in the first half of the dark phase (Fig. 2B), a period
during which mice are normally active most of the time and the
biggest part of their total wheel-running activity is observed
(Fig. 4A, C).
It has recently been shown that alterations of the dynamics of
the sleep homeostat can also alter the distribution of sleep [49]. As
discussed above, the reduced levels of EEG delta power during
baseline might be a consequence of the changes in the distribution
of sleep in Prkg1 mutant mice. The fact that we did observe
differences in the compensatory rebound in sleep time after sleep
deprivation, however, suggests that PRKG1 also affects at least
some aspects of sleep homeostasis. The contribution of this effect
to the pronounced reduction in sleep and wake quality observed
during baseline remains to be quantified.
Taken together, we present evidence that abolition of PRKG1
in the nervous system distinctly alters the sleep-wake or rest-
activity distribution in mice. The reduction in the diurnal
and light periods during one day. Data is expressed as average counts/minute over a ten-minute interval. The inset graph shows ZT 0.33–11.33 on a
magnified scale. Gray diamonds indicate statistically significant differences between genotypes (p,0.05 as determined by unpaired t-test). n=19 for
controls, n=18 for Prkg1
BKO mutants; ZT, Zeitgebertime. (F) Relative drinking activity during the light phase of Prkg1
BKO and Prkg1
SMr mice as
compared to their respective litter-matched controls. Values are expressed as % of total drinking volume consumed during the light phase. ***
p,0.001, ** p,0.01 as determined by unpaired t-test. n=8 for both Prkg1
BKO mutants and the respective controls, n=10 for Prkg1
SMr mutants, n=21
for the respective controls. Note that the absolute drinking volume during 24 hours was not different between genotypes. (G) Representative
recordings of drinking activity over six days for all four genotypes. Black and white bars on top depict the distribution of dark and light periods during
the recording. For better orientation, those parts of the diagrams recorded during darkness are additionally shaded.
doi:10.1371/journal.pone.0004238.g005
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of the circadian output strength, a hypothesis that is supported by
the effects of Prkg1 deficiency on circadian rhythm amplitude
under constant conditions. Especially, the inability of Prkg1-
deficient mice to sustain long periods of wakefulness is consistent
with the notion that the SCN primarily promotes wakefulness, as
lesion studies suggest [50,51].
Materials and Methods
Mice
The generation of mice carrying a conditional loxP-flanked
(‘‘floxed’’) Prkg1 allele (L2) or a recombined Prkg1 null allele (L2;
see Fig. 1A) and their genotyping by PCR has been described [52].
Mice with modified Prkg1 alleles were crossed with Nes-Cre mice [22]
to generate conditional Prkg1 mutants lacking PRKG1 in the brain
(Prkg1
BKO mice; genotype: Prkg1
L2/L2; Nes-Cre
tg/0) and litter-
matched control mice (genotype: Prkg1
+/L2; Nes-Cre
tg//0). The Nes-
Cre transgene was detected by PCR analysis with cre-specific primers
[53]. To monitor the recombination pattern of the Nes-Cre line, it
was crossed with ROSA26 Cre reporter (R26R) mice [23], which
express b-galactosidase upon Cre-mediated recombination of a lacZ
reporter gene. The Prkg1 s m o o t hm u s c l e( S M )r e s c u e( Prkg1
SMr)m i c e ,
which express an SM-specific Prkg1 transgene on a Prkg1
L2/L2
background, and litter-matched Prkg1
+/L2or Prkg1
+/+control animals
were generated as described [21]. Male mutant and control
littermates were used for all behavioral analyses. Experiments in
Switzerland were performed according to the state laws of the
Cantons of Fribourg and Vaud. Experiments performed in Germany
were done in accordance with German animal protection law.
Immunostaining and X-Gal staining
Expression of PRKG1 was detected in brain extracts by
Western blotting and in paraffin sections by immunohistochem-
istry with a polyclonal antibody against recombinant PRKG1
(PRKG1 common antibody) as described previously [18]. b-
galactosidase activity was detected by staining brains (cut into
halves or cryosectioned) with 5-bromo-4-chloro-3-indolyl b-D-
galactoside (X-Gal) as reported [54].
Analysis of sleep/EEG
Animals and housing conditions. Adult male Prkg1
SMr and
control mice (n=7 for both) of 14–16 weeks of age were used in
this study. After surgery, mice were kept individually in
polycarbonate cages (31618618 cm) with food and water
available ad libitum, and maintained on a 12 h light–12 h dark
cycle (LD 12:12; lights on at 9:00 AM) at an ambient temperature
of 24.5–25.5uC.
Surgery. Electroencephalogram (EEG) and electromyogram
(EMG) electrodes were implanted under deep anaesthesia with a
mixture of ketamine and xylazine (ip, 75 and 10 mg/kg,
respectively, at a volume of 8 ml/g). Two gold-plated miniature
screws (diameter 1.1 mm) that served as EEG electrodes were
screwed into the cranium over the right cerebral hemisphere, in a
fronto-parietal position (according to [55]). Four additional anchor
screws were implanted; one over the right hemisphere and three
over the left hemisphere. Two semi-rigid gold wires served as
EMG electrodes and were inserted between two neck muscles.
The EEG and EMG electrodes were soldered to a connector and
the anchor screws were cemented to the skull. 4 to 8 days of
recovery from surgery were allowed before animals were
connected to the recording leads. A minimum of 6 adaptation
days (or 10 including recovery from surgery) was scheduled before
data collection.
Experimental protocol. EEG and EMG signals were
recorded continuously for 2 days starting at light onset (0 h).
The first day (0–24 h) served as baseline. Starting at light onset of
the second day animals were kept awake for 6 h (sleep deprivation:
24–30 h) by gentle handling [25]. The remaining 18 h of the
second day (30–48 h) were considered recovery.
Data analyses. The analogous EEG and EMG signals were
digitized at 2000 Hz and subsequently stored at 200 Hz on hard
disc. The EEG was subjected to a discrete-Fourier transformation
(DFT) yielding power spectra (range: 0.25–100 Hz, resolution:
0.25 Hz, window function: hamming; spectral analysis limited to
the 0.75–45.0 Hz range for the current report) for consecutive 4-s
epochs. Hardware (EMBLA
TM) and software (Somnologica-3
TM)
were purchased from Medcare/Flaga (Island). Based on the EEG
and EMG signals, the animal’s behavior was classified either as
REMS, NREMS, or wakefulness, for consecutive 4-s epochs
according to standard criteria [55]. States were scored by visual
inspection of the EEG and EMG signals displayed on a PC
monitor. 4-s epochs containing EEG artifacts were marked so they
could be excluded from EEG spectral analyses.
Amount and distribution of NREMS, REMS, and wakefulness
were calculated for 1, 12, and 24 h intervals. The baseline
distribution of sleep was further analyzed by expressing hourly
values of the three behavioral states as % of the total time spent in
each state during baseline (=100%). Subsequently, hourly
percentages were accumulated and genotype differences of the
resulting curves calculated to assess the times at which the two
distributions deviated. The recovery time course for sleep time lost
during the sleep deprivation was calculated by contrasting the
hourly values of NREMS and REMS observed during recovery
(30–48 h) to the values observed during the corresponding
baseline hours (6–24 h). The recovery-baseline differences were
accumulated to examine the recovery time course. NREMS
quality during baseline was assessed by determining its fragmen-
tation. For the number of NREMS episodes ,1 min (i.e., 15 or
less consecutive 4-s epochs scored as NREMS) and .1 min were
calculated [25]. Both variables were expressed per hour of
NREMS to correct for eventual individual differences in time
spent in this state.
EEG frequency content was analyzed using the DFT. For each
behavioral state an EEG spectral profile (0.75–45 Hz) was
constructed by averaging all artifact free 4-s epochs scored as that
state. An additional inclusion criteria was that the 4-s epoch under
consideration should be immediately preceded and followed by a
4-s epoch that was of the same state and equally artifact free.
Spectra were calculated as absolute values, in units of micro-volts
square per 0.25 Hz, or as relative values to correct for inter-
individual differences in the absolute EEG level. The latter
analysis quantifies the relative contribution of each frequency to
the overall EEG signal during each of the three behavioral states.
All values are expressed relative to the weighted mean average of
total EEG power in all vigilance states [55].
EEG delta power during NREM sleep was calculated by
averaging power density in the frequency bins from 1 to 4 Hz.
Values were individually normalized by expressing them as a
percentage of the mean delta power over 4-s epochs scored as
NREMS in the last 4 h of the baseline light period; i.e., a time at
which the lowest average levels are reached during baseline. The
time course of EEG delta power in NREMS was assessed by
dividing the 12 h light and dark periods into 12 (baseline light
period; 0–12 h), 8 (recovery light 30–36 h and dark period 36–
48 h), or 6 (for the baseline dark period; 12–24 h) intervals to
which an equal number of 4-s epoch scored as NREMS
contributed within individual mice (i.e., percentiles). The same
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NREMS in the 1.0–2.25 Hz and 2.5–4.0 Hz frequency ranges
and for the 1.0–2.25/2.5–4.0 Hz power ratio.
All statistical analyses were done using SAS (SAS Institute Inc.;
version 9.1). All graphics including non-linear fitting (for
illustration purposes) were done using SigmaPlot (SyStat Software,
Inc.; version 9).
Wheel-running
Animals. Animals used were adult male Prkg1
SMr and control
mice (n=6 for both) and adult male Prkg1
BKO mice (n=18) and
their respective controls (n=20) between 7–16 weeks of age at the
beginning of the experiments.
Data collection and analysis. Analysis of locomotor activity
parameters was done by monitoring wheel-running activity as
described in [56] using the ClockLab software (Actimetrics) for all
subsequent calculations. Briefly, for the analysis of free-running
rhythms, animals were entrained to LD 12:12 and subsequently
released into constant darkness (DD) or constant light (LL).
Internal period length (t) was determined from a regression line
drawn through the activity onsets of 10 days of stable rhythmicity
under constant conditions. Total and daytime activity as well as
activity distribution profiles and chi square periodograms were
calculated using the respective inbuilt functions of the ClockLab
software. Onset errors were determined manually from the
actograms and refer to the difference between lights off and the
actual onset of activity in LD and to the deviation of the actual
onset from a regression line drawn through 10 consecutive onsets
in LL/DD. Length and frequency of rest bouts during the activity
phase were also evaluated manually from the actograms of animals
kept in LD 12:12. For chronic jet-lag, animals were subjected to a
lighting schedule mimicking a 4 h-forward shift every 2 days for
18 days. Phase shifts were determined according to the Aschoff
Type II protocol [57]. Animals were entrained to LD 12:12,
subjected to a light pulse (15 min, 400 lux) at Zeitgebertime (ZT)
14 and subsequently released into DD for 14 days. They were
again entrained to LD12:12 and the procedure was repeated for a
light pulse at ZT22. To monitor the effect of a simple LD-DD-
transition, animals were entrained to LD 12:12 and released into
DD without prior adminstration of a light pulse. For the
calculation of phase shifts, a regression line was drawn through
10 consecutive onsets in DD; the first 2 days in DD were regarded
as transition and not taken into account. Phase shifts were
expressed as the differences between the regression lines (and thus
the hypothetical onsets of activity) on the first day of DD after a
normal LD-DD transition and after a light pulse. Statistical
analysis was perfomed using Prism 4 for Macintosh (Graph Pad
software, Inc.; version 4.0a).
Open-field test
Animals. Animals used were 9 months-old male Prkg1
SMr
(n=5) and control mice (n=6).
Data collection and analysis. General locomotor activity was
assessed using an infrared beam-operated system (Institute of
Physiology, University of Fribourg, Switzerland) in which a
standard cage (16622.5 cm) was placed inside a frame containing
96 infrared LEDs in 2 levels of 24624 LEDs. The first level was at a
height of 2.8 cm, the second level at a height of 5.5 cm; horizontal
distance between LEDs was 8.5 mm on the long side and 6.25 mm
on the short side of the cage. The test was performed in cages with
Whatman paper as bedding soas not to disturbthe readings. Animals
were allowed to get used to the absence of bedding for one day prior
to the experiment and were subjected to the test on the next day
between 10 AM and 1 PM (ZT 4–7). At the beginning of the test
session, animals were placed in the middle of the test cage, and
locomotor activity (inthe formin infrared beam breaks) was recorded
for 30 minutes using a Visual Basics-based software (ActivityX16,
provided by Laurent Monney, Institute of Physiology, University of
Fribourg, Switzerland). Data was transmitted as serial information
using an RS232 protocol and evaluated using a C sharp-based
software (Read Activity Results File version 1.4.4, also provided by
Laurent Monney, Institute of Physiology, University of Fribourg,
Switzerland). Total distance travelled, mean speed and percentage of
total time spent active were calculated for each animal.
Drinking activity
Animals. Animals used were 6–13 week-old male Prkg1
SMr
mice (n=10) and litter-matched control mice (n=21), and 10–36
week-old male Prkg1
BKO mice (n=8) and litter-matched control
mice (n=8).
Data collection and analysis. Drinking activity and volume
of individually housed mice were monitored continuously using a
computerized system (TSE Technical & Scientific Equipment
GmbH, Bad Homburg, Germany). Animals were monitored for
4–6 days with food and water available ad libitum, and maintained
on an LD 14:10 cycle (lights on at 6:00 AM).
Supporting Information
Figure S1 EEG spectral composition of wakefulness (W), non-
Rapid-Eye-Movement sleep (NREMS, N), and REMS (R) during
baseline. (A) Absolute EEG power density for W (gray), N (blue),
and R (red) in control (upper panel) and Prkg1SMr (middle panel)
mice. The lower panel depicts the % Prkg1SMr/control difference
spectra. Genotype affected absolute EEG spectra of NREMS only
[2-way ANOVA with factors ‘genotype’ (P=0.37, 0.0072, and
0.44) and ‘EEG frequency’ (repeated measures, 0.75–45 Hz:
P,0.0001) and their interaction (P=0.18, 0.0009, and 0.50); P-
values for W, N, and R, respectively]. Horizontal bars at the
bottom connect frequency bins in which values differed between
genotypes (P,0.05; post-hoc 2-sided t-tests), color coded accord-
ing to behavioral state. (B) Relative EEG spectra. Within each
mouse, behavioral state, and frequency bin, EEG power density
was expressed as a % of the total EEG power over all frequency
bins (0.75–45 Hz) and behavioral states in baseline. This EEG
reference values was weighted so that an equal number of 4 s of
each state contributed to the total in all mice (see Methods).
Normalizing reduces the variance in the data due to inter-
individual differences in EEG signal strength but precludes the
analysis of genotype effects on absolute EEG values. Analyses-of-
variance indicated that also for these normalized EEG spectra,
genotype altered the spectral composition of NREMS only [2-way
ANOVA with factors ‘genotype’ (P=0.12, 0.084, and 0.19) and
‘EEG frequency’ (repeated measures, 0.75–45 Hz: P,0.0001) and
their interaction (P=0.093, 0.011, and 0.32); P-values for W, N,
and R, respectively]. During NREMS, relative EEG power density
in Prkg1SMr mice (black line) was reduced in the low delta (0.75–
2.0 Hz) and increased in the gamma (39.0–60.25 Hz) frequency
range compared to control mice (gray line). Gray horizontal bars
at the bottom connect frequency bins for which values differed
between genotypes (P,0.05; post-hoc 2-sided t-tests).
Found at: doi:10.1371/journal.pone.0004238.s001 (1.33 MB TIF)
Figure S2 Frequency distribution of waking (W, top), Rapid-
Eye-Movement sleep (REMS, R, bottom), and non-REMS
(NREMS, N, middle panels) episode duration in baseline. Mean
(+SEM) number of episode expressed per hour of the respective
behavioural state for nine consecutive time bins (4 s, 8–12 s, 16–
28 s, 32–60 s, 64–124 s, 128–252 s, 256–508 s, 512–1020 s, and
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panels; % of the individual total time spent in each behavioural
state over the 24 h baseline). The frequency distribution of waking
and NREMS episode length was affected by genotype [2-way
ANOVA with factors ‘genotype’ (P=0.033 and 0.017) and
‘episode duration’ (repeated measures, 9 bins; P,0.0001) and
their interaction (P=0.15 and 0.0065); P-values for W and N,
respectively]. The distribution of the relative amount of time spent
awake or in NREMS also varied with genotype (interaction
between factors ‘genotype’ and ‘episode duration’: P,0.0001 and
0.035 for W and N, respectively). REMS episode duration was not
affected by genotype. Red asterisks indicate significant genotype
differences (P,0.05; post-hoc t-tests).
Found at: doi:10.1371/journal.pone.0004238.s002 (1.70 MB
DOC)
Figure S3 Time course of EEG delta power. Given the
frequency specific effects of genotype on EEG power density
within the delta frequency range (see Fig. 2 and Fig. S1), the time
course of EEG delta power was analyzed separately for slow (1.0–
2.25 Hz) and fast (2.5–4.0 Hz) delta frequencies. (A) Mean
(61SEM) relative levels of slow (closed symbols) and fast (open
symbols) EEG delta power for the 48 h of the experiment (control:
upper panel, Prkg1SMr: lower panel). Values within each
frequency band were expressed as % of their respective levels
reached between baseline hours 8–12 h (see Methods). Changes in
slow delta power respond less accurately to changes in sleep-wake
distribution as compared to the power in the faster frequencies.
This is especially clear in Prkg1SMr mice in which the typical
decrease in the light period and increase in the dark period was
absent in slow delta power while changes in activity in the faster
delta frequencies resembled more that in control mice most
notably during recovery. Filled and open diamonds at the bottom
indicate times at which values significant differed between
genotypes for the slow and fast delta bands, respectively
(P,0.05; post-hoc 2-sided t-tests). [3-way ANOVA with factors
‘genotype’? (P=0.27 and 0.038), ‘SD’ (recovery vs. baseline;
repeated measures; P=0.091 and 0.038) and ‘time’ (30–48 vs. 0–6
and 12–24; repeated measures: P,0.0001); interactions ‘genoty-
pe’6‘SD’ (P=0.038 and 0.33), ‘genotype’6‘time’ (P=0.095 and
0.096), ‘SD’6‘time’ (P=0.0017 and ,0.0001); P-values for slow
and fast delta power, respectively]. B: Time course of the fast-to-
slow delta power ratio. This ratio, which is known to increase
immediately after long period of wakefulness ([58]; see after SD),
was significantly higher in Prkg1SMr due to the larger suppression
of slow delta activity compared to fast delta (see Fig. 2). [3-way
ANOVA with factors ‘genotype’ (P=0.0043), ‘SD’ (recovery vs.
baseline; repeated measures; P=0.0004), and ‘time’ (30–48 vs. 0–6
and 12–24; repeated measures: P,0.0001); interactions ‘genoty-
pe’6‘SD’ (P=0.018), ‘genotype’6‘time’ (P=0.12), ‘SD’6‘time’
(P=0.0017)]. Gray diamonds at the bottom indicate times at
which ratios significant differed between genotypes (P,0.05; post-
hoc 2-sided t-tests). In all panels, gray areas denote the dark
periods. Recovery values labeled red are significantly different
from corresponding baseline values (with respect to sleep onset;
P,0.05; post-hoc 2-sided paired t-tests).
Found at: doi:10.1371/journal.pone.0004238.s003 (1.29 MB TIF)
Figure S4 Prkg1SMr mutant mice do not display differences in
general locomotor activity. General locomotor activity parameters
of control and Prkg1SMr mutant mice were determined by
monitoring their activity in an open field using a system based on
infrared beam breaks during 30 minutes. Total distance travelled
(A), mean speed (B) and the percentage of time during which the
mouse was active (C) were calculated for each animal. n=6 for
controls, n=5 for Prkg1SMr mutants.
Found at: doi:10.1371/journal.pone.0004238.s004 (0.13 MB TIF)
Figure S5 Clock resetting in Prkg1BKO mutant mice. Phase-
shifting properties of control and Prkg1BKO mutant mice were
assessed using an Aschoff Type II protocol. Mice were entrained to
LD 12:12, subjected to 15-minutes light pulses at the indicated
ZTs and subsequently released into DD. They were additionally
subjected to an LD-DD transition without prior administration of
a light pulse. Phase shifts are expressed as the difference between
the onsets of activity observed on the first day after the light pulse
and the first day of DD without light pulse. n=11 for controls,
n=9 for Prkg1BKO mutants.
Found at: doi:10.1371/journal.pone.0004238.s005 (0.10 MB TIF)
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